CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 53 filers reported holding CATABASIS PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $4,241,000 | +1891.1% | 2,009,747 | +2636.8% | 0.00% | – |
Q1 2021 | $213,000 | -15.1% | 73,434 | -37.5% | 0.00% | – |
Q4 2020 | $251,000 | +15.1% | 117,583 | +234.0% | 0.00% | – |
Q3 2020 | $218,000 | +96.4% | 35,200 | +105.2% | 0.00% | – |
Q2 2020 | $111,000 | +85.0% | 17,157 | +68.4% | 0.00% | – |
Q4 2019 | $60,000 | – | 10,190 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Eversept Partners, LP | 522,042 | $1,117,170 | 0.13% |
XTX MARKETS LLC | 26,041 | $56,000 | 0.12% |
Samsara BioCapital, LLC | 300,000 | $642,000 | 0.06% |
Ikarian Capital, LLC | 650,000 | $1,392,000 | 0.06% |
Opaleye Management Inc. | 187,750 | $402,000 | 0.05% |
SABBY MANAGEMENT, LLC | 108,026 | $231,000 | 0.04% |
Anson Funds Management LP | 97,601 | $209,000 | 0.04% |
Virtu Financial LLC | 83,221 | $178,000 | 0.02% |
GSA CAPITAL PARTNERS LLP | 47,084 | $101,000 | 0.02% |
WEXFORD CAPITAL LP | 19,512 | $42,000 | 0.01% |